Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2Study of Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss (MANTRA-4)

NCT06090318 is registered in ClinicalTrials.gov with Rain Oncology Inc as lead sponsor.

NCT NCT06090318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06090318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2Study of Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss (MANTRA-4)
Lead sponsor
Rain Oncology Inc
Phase
Phase 1/2
Overall status
Withdrawn
Start date
May 19, 2023
Completion date
May 30, 2023
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, cdkn2a, gastric cancer, hnscc, melanoma, mesothelioma, nsclc, pancreas adenocarcinoma, renal cell carcinoma, urothelial carcinoma bladder